Dahle Jostein, Abbas Nasir, Bruland Øyvind S, Larsen Roy H
Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Montebello, 0310 Oslo, Norway.
Curr Radiopharm. 2011 Oct;4(4):321-8. doi: 10.2174/1874471011104040321.
Radioimmunotherapy based on α-particle emitters has excellent properties as a treatment against micrometastatic and disseminated cancers because of the short path length (50 - 80 μm) and high linear energy transfer (∼ 100 keV/ μm). Alpha-particles produce clustered DNA double-strand breaks and highly reactive hydroxyl radicals when hitting biological tissue. Hence, targeted α-particle therapy offers the potential of selective tumor cell killing with low damage to surrounding normal tissue. The ideal applications for targeted α-therapy are in treating neoplastic cells in circulation or when cancer cells are present as free-floating cells or spread along compartment walls. This review will provide a brief overview of the most promising radionuclides for targeted α-therapy and compare their relative biological effectiveness (RBE) and normal tissue toxicity.
基于α粒子发射体的放射免疫疗法作为一种治疗微转移癌和播散性癌症的方法具有优异的特性，这是因为其短程长度（50 - 80μm）和高线性能量传递（约100keV/μm）。α粒子撞击生物组织时会产生成簇的DNA双链断裂和高活性的羟基自由基。因此，靶向α粒子疗法具有选择性杀伤肿瘤细胞而对周围正常组织损伤较小的潜力。靶向α疗法的理想应用是治疗循环中的肿瘤细胞，或者癌细胞以游离细胞形式存在或沿腔壁扩散的情况。本综述将简要概述用于靶向α疗法最有前景的放射性核素，并比较它们的相对生物效能（RBE）和正常组织毒性。
